聚焦超声丘脑毁损术治疗药物难治性震颤型帕金森病的随机临床试验
该随机对照试验将27例药物难治性震颤型帕金森病患者按2:1分配至单侧聚焦超声丘脑毁损术组或假手术组,12个月随访评估安全性和疗效。早期2例(8%)出现轻度偏瘫,经调整磁共振测温监测后改善,其他持续不良事件包括口面部感觉异常等。
要点
- 聚焦超声丘脑毁损术可改善药物难治性震颤型帕金森病患者的手部震颤,即使存在安慰剂反应。
- 早期2例(8%)出现轻度偏瘫,促使增加磁共振测温监测轴,其他持续不良事件包括口面部感觉异常(20%)等。
核心结论
- 聚焦超声丘脑毁损术治疗震颤型帕金森病,在CRST评估中显示药物难治性震颤改善,即使存在安慰剂反应。
研究设计与样本
- 随机对照试验,从院内数据库筛选326例,53例同意筛查,26例不合格,27例按2:1随机分配至单侧聚焦超声丘脑毁损术(20例)或假手术(7例),在2个中心进行,时间2012年10月18日至2015年1月8日。
- 采用意向性分析,主要结局评估双盲。
主要发现
- 27例患者中26例(96%)为男性,中位年龄67.8岁(IQR 62.1-73.8)。
- 用药状态下中位UPDRS运动评分:毁损术组从基线23分(IQR 15.5-34.0)改善8分(IQR 0.5-11.0),假手术组从基线25分(IQR 15.0-33.0)改善1分(IQR -5.0至9.0)。
- 早期研究中内囊加热导致2例(8%)轻度偏瘫,经改善并促使在磁共振测温中监测额外轴。
- 其他持续不良事件:口面部感觉异常4例(20%)、手指感觉异常1例(5%)、共济失调1例(5%)。
临床怎么用
- 对于药物难治性震颤型帕金森病患者,单侧聚焦超声丘脑毁损术可考虑作为改善震颤的治疗选择。
- 治疗中需注意内囊加热可能导致偏瘫,建议在磁共振测温中监测额外轴以降低风险。
- 需关注口面部感觉异常、手指感觉异常和共济失调等持续不良事件。
局限性
- 样本量较小(27例),且96%为男性,可能限制普遍性。
- 假手术组在揭盲后接受开放标签治疗,可能影响长期比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trials have confirmed the efficacy of focused ultrasound (FUS) thalamotomy in essential tremor, but its effectiveness and safety for managing tremor-dominant Parkinson disease (TDPD) is unknown. OBJECTIVE: To assess safety and efficacy at 12-month follow-up, accounting for placebo response, of unilateral FUS thalamotomy for patients with TDPD. DESIGN, SETTING, AND PARTICIPANTS: Of the 326 patients identified from an in-house database, 53 patients consented to be screened. Twenty-six were ineligible, and 27 were randomized (2:1) to FUS thalamotomy or a sham procedure at 2 centers from October18, 2012, to January 8, 2015. The most common reasons for disqualification were withdrawal (8 persons [31%]), and not being medication refractory (8 persons [31%]). Data were analyzed using intention-to-treat analysis, and assessments were double-blinded through the primary outcome. INTERVENTIONS: Twenty patients were randomized to unilateral FUS thalamotomy, and 7 to sham procedure. The sham group was offered open-label treatment after unblinding. MAIN OUTCOMES AND MEASURES: The predefined primary outcomes were safety and difference in improvement between groups at 3 months in the on-medication treated hand tremor subscore from the Clinical Rating Scale for Tremor (CRST). Secondary outcomes included descriptive results of Unified Parkinson's Disease Rating Scale (UPDRS) scores and quality of life measures. RESULTS: Of the 27 patients, 26 (96%) were male and the median age was 67.8 years (interquartile range [IQR], 62.1-73.8 years). On-medication median tremor scores improved 62% (IQR, 22%-79%) from a baseline of 17 points (IQR, 10.5-27.5) following FUS thalamotomy and 22% (IQR, -11% to 29%) from a baseline of 23 points (IQR, 14.0-27.0) after sham procedures; the between-group difference was significant (Wilcoxon P = .04). On-medication median UPDRS motor scores improved 8 points (IQR, 0.5-11.0) from a baseline of 23 points (IQR, 15.5-34.0) following FUS thalamotomy and 1 point (IQR, -5.0 to 9.0) from a baseline of 25 points (IQR, 15.0-33.0) after sham procedures. Early in the study, heating of the internal capsule resulted in 2 cases (8%) of mild hemiparesis, which improved and prompted monitoring of an additional axis during magnetic resonance thermometry. Other persistent adverse events were orofacial paresthesia (4 events [20%]), finger paresthesia (1 event [5%]), and ataxia (1 event [5%]). CONCLUSIONS AND RELEVANCE: Focused ultrasound thalamotomy for patients with TDPD demonstrated improvements in medication-refractory tremor by CRST assessments, even in the setting of a placebo response. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01772693.
引用
- Bond AE, Shah BB, Huss DS, et al. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 29084313. doi:10.1001/jamaneurol.2017.3098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。